Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
226 hedge funds and large institutions have $3.3B invested in Amicus Therapeutics in 2023 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 95 increasing their positions, 58 reducing their positions, and 29 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 58
1.21% more ownership
Funds ownership: 104.1% → 105.31% (+1.2%)
3% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 29
2% less funds holding
Funds holding: 230 → 226 (-4)
8% less capital invested
Capital invested by funds: $3.57B → $3.3B (-$268M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
31% less call options, than puts
Call options by funds: $4.41M | Put options by funds: $6.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$27.7M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$21.3M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$19.2M |
| 4 |
Millennium Management
New York
|
+$18.1M |
| 5 |
O
OrbiMed
New York
|
+$8.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$23.5M |
| 2 |
Morgan Stanley
New York
|
-$16.5M |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.8M |
| 4 |
Nordea Investment Management
Stockholm,
Sweden
|
-$7.77M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.3M |
FOLD Hedge Fund Activity: Q1 2023 in Review
226 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q1 2023, worth a combined $3.3B — down 7.5% from $3.57B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new FOLD positions and 29 closed out — a net gain of 1 holder — while 95 added to existing stakes and 58 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $27.7M. The largest seller was Redmile Group, cutting an estimated $23.5M.
- 226 institutional investors held Amicus Therapeutics (FOLD) as of Q1 2023, down from 230 in Q4 2022.
- Funds reported $3.3B of Amicus Therapeutics stock for Q1 2023, down 7.5% quarter-over-quarter.
- 30 funds opened new Amicus Therapeutics positions in Q1 2023 and 29 closed out, a net change of +1 holder.
- The largest Amicus Therapeutics buyer in Q1 2023 was Point72 Asset Management, an estimated $27.7M added.
- The largest Amicus Therapeutics seller in Q1 2023 was Redmile Group, an estimated $23.5M sold.
Based on aggregated 13F filings for Q1 2023.